Greg Vogt
04-18

$Palantir Technologies Inc.(PLTR)$

The FDA's guidelines to replace animal testing suggest that preclinical data can be provided based on AI models and organoid experiment data. The obvious beneficiaries in this round are AI pharmaceuticals like Recursion (RXRX). Palantir (PLTR), which had previously stated its involvement, is now expanding its commercial scope. It can now fully lay out contracts outside of government and military sectors, such as the major American supermarket chains like Walmart (WMT), large pharmaceutical companies under the current situation, and a considerable number of manufacturing companies. Although it's challenging, it's still necessary to plan ahead. If the situation in the US continues to deteriorate, it will be much more difficult to expand later.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment